Article Contents ::
- 1 The Brand Name CONJUGASE Has Generic Salt :: Conjugated
- 2 CONJUGASE Is From Company Elder Priced :: Rs. 210
- 3 CONJUGASE have Conjugated is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name CONJUGASE Has Generic Salt :: Conjugated
CONJUGASE Is From Company Elder Priced :: Rs. 210
CONJUGASE have Conjugated is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Conjugated | TAB | Rs. 210 | 28 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 28 |
| CONJUGASE | Elder | 0.625MG | 28 | Rs. 210 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Elder :: CONJUGASE | Conjugated | #N/A | #N/A |
Indications for Drugs ::
Osteoporosis, Fungal infections, Itching, Burning, Hot flashes, Vaginal dryness, Vaginal atrophy, Menopausal symptoms, Female hypogonadism, Metastatic breast carcinoma, Ovarian failure, Prostate carcinoma, Primary ovarian failure, Hormone replacement therapy, Oral contraceptives
Drug Dose ::
Adult: PO Menopausal vasomotor symptoms 0.45 mg/day, up to 1.25 mg/day. Attempt to discontinue medication at 3-6-mth intervals. Vulvular and vag atrophy 0.3 mg/day. Female hypogonadism 0.3-0.625 mg/day in a cyclical regimen. Add progestin treatment once skeletal maturity is achieved. Female castration; Primary ovarian failure 1.25 mg/day in a cyclical regimen. Palliation in prostate carcinoma 1.25-2.5 mg 3 times/day. Osteoporosis prophylaxis in postmenopausal women Initial: 0.3 mg/day in a cyclical or continuous regimen depending on patient’s condition. IV/IM Abnormal uterine bleeding 25 mg, may repeat in 6-12 hr if needed.
Contraindication ::
Severe liver impairment; breast carcinoma; thromboembolic disorders; CV disease; undiagnosed vag bleeding; estrogen-dependent neoplasms; hypersensitivity; pregnancy.
Drug Precautions ::
Asthma, epilepsy, migraine; heart or kidney dysfunction; CV disease; cerebrovascular disorders; diabetes, hypercalcaemia; gall bladder disease; porphyria. Childn. Lactation.
Drug Side Effects ::
Abnormal bleeding; vomiting, nausea; tender breasts, wt gain, fluid retention; headache, depression. Males: Gynaecomastia, impotence. Potentially Fatal: Unopposed replacement therapy in postmenopausal women associated with increased risk of endometrial and breast cancer.
Pregnancy category ::
0
Drug Mode of Action ::
Estrogens modulate pituitary secretion of gonadotropins, leutinising hormones and follicle-stimulating hormones through -ve feedback mechanism, thus reducing elevated levels of hormones in postmenopausal women during oestrogen replacement therapy.
Drug Interactions ::
Rifampicin, barbiturates increase rate of metabolism. Potentially Fatal: May reduce the efficacy of anticoagulants.
